American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
